

February 1998

Developmental and Hormonal Regulation of Transforming Growth Factor- β 1 (TGF β 1), -2, and -3 Gene Expression in Isolated Prostatic Epithelial and Stromal Cells: Epidermal Growth Factor and TGF β Interactions

Naoki Itoh

Washington State University, Pullman

Urvashi Patel

Washington State University, Pullman

Andrea S. Cupp

University of Nebraska-Lincoln, acupp2@unl.edu

Michael K. Skinner

Washington State University, Pullman

Follow this and additional works at: <http://digitalcommons.unl.edu/animalscifacpub>

 Part of the [Animal Sciences Commons](#)

Itoh, Naoki; Patel, Urvashi; Cupp, Andrea S.; and Skinner, Michael K., "Developmental and Hormonal Regulation of Transforming Growth Factor- β 1 (TGF β 1), -2, and -3 Gene Expression in Isolated Prostatic Epithelial and Stromal Cells: Epidermal Growth Factor and TGF β Interactions" (1998). *Faculty Papers and Publications in Animal Science*. 162.

<http://digitalcommons.unl.edu/animalscifacpub/162>

This Article is brought to you for free and open access by the Animal Science Department at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Papers and Publications in Animal Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Developmental and Hormonal Regulation of Transforming Growth Factor- β 1 (TGF β 1), -2, and -3 Gene Expression in Isolated Prostatic Epithelial and Stromal Cells: Epidermal Growth Factor and TGF β Interactions*

NAOKI ITOH[†], URVASHI PATEL, ANDREA S. CUPP, AND MICHAEL K. SKINNER

Center for Reproductive Biology, Department of Genetics and Cell Biology, Washington State University, Pullman, Washington 99164-4231

ABSTRACT

Growth factors are postulated to mediate stromal-epithelial interactions in the prostate to maintain normal tissue physiology. Transforming growth factor- β (TGF β) has been shown to influence the prostate and probably mediate stromal-epithelial interactions. TGF β 1 messenger RNA (mRNA) expression is stimulated after castration and can be suppressed by *in vivo* treatment with androgens. The hypothesis tested is that TGF β is regulated not only by androgen, but also by a network of locally produced growth factors that influence prostatic growth and differentiation. Epithelial and stromal cells from 20-day-old rat ventral prostate were isolated and used to test this hypothesis. The expression of mRNA for TGF β 1, -2, and -3 was analyzed by a quantitative RT-PCR procedure. Observations from this assay demonstrate that both epithelial and stromal cells express the mRNA for TGF β 1, -2, and -3. TGF β 1 mRNA expression was constant during development of the prostate. TGF β 2 mRNA expression was elevated at birth, then declined and elevated again at 100 days of age. TGF β 3 mRNA expression was high during puberty and young adult ages then declined at 100 days of age. TGF β 2 and TGF β 3 expression are inversely related during prostate development. After castration of 60-day-old rats, both TGF β 1 and TGF β 2 mRNA were enhanced. Interestingly, TGF β 3 mRNA was significantly suppressed after castra-

tion. Epidermal growth factor (EGF) stimulated TGF β 1 mRNA expression in stromal cells (6-fold increase), whereas keratinocyte growth factor stimulated TGF β 2 mRNA in epithelial cells. TGF β inhibited both testosterone- and EGF-stimulated prostatic stromal and epithelial cell growth. EGF and TGF β also inhibited prostatic ductal morphogenesis and growth in organ culture. Immunocytochemical localization of TGF β in 20-day-old prostate demonstrated predominately stromal localization of the protein.

These results indicate that the isoforms of TGF β 2 and TGF β 3 are differentially regulated during prostate development, suggesting distinct regulatory mechanisms. Testosterone did not affect TGF β expression in cultured prostatic cells. These observations suggest that the *in vivo* effects of castration on TGF β s are regulated indirectly through a complex network of growth factors, not simply by direct androgen depletion. The ability of EGF to inhibit prostatic ductal morphogenesis and growth in organ culture is postulated to be in part mediated by the increase in TGF β 1 expression. In summary, a network of growth factor-mediated stromal-epithelial interactions is needed to maintain prostate growth and development. TGF β is postulated to have an important role in this process. (*Endocrinology* 139: 1378–1388, 1998)

ANDROGENS are essential for the growth, development, and function of the prostate gland (1). The actions of androgen on the prostate appear to be in part mediated through stromal-epithelial interactions (2–4). Several growth factors that are produced by stromal cells in response to androgen can influence epithelial cells of the prostate (5). Epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), keratinocyte growth factor (KGF), and insulin-like growth factors I and II can all stimulate growth of prostatic epithelial cells (6–8). In contrast, transforming growth factor- β (TGF β) has been shown to have inhibitory effects on prostatic stromal cells and epithelial cells (6). Androgens have been shown to regulate growth factor gene expression in the prostate (9–12). In addition, growth factors influence growth factor expression. For example, TGF β 1 enhances

bFGF expression in cultured human prostate stromal cells (13, 14). The hypothesis was developed that a network of locally produced growth factors is required for prostate growth and differentiation.

Three isoforms of TGF β (TGF β 1, -2, and -3) have been identified in mammals, and their actions on cultured cells are similar in activity and potency (15). The biological actions of TGF β are numerous and include control of cell proliferation, adhesion, and differentiation (15). TGF β s generally have growth inhibitory activity on epithelial, neuronal, and lymphoid cells. TGF β activates the synthesis of extracellular matrix components (16). Recently, it was found that inhibition of cyclin-dependent kinases by TGF β results in growth arrest of cells in the G1 phase of the cell cycle (17, 18). TGF β has dramatic effects on the prostate (19, 20) through inhibiting the growth of both epithelial and stromal cells (13, 21, 22). These observations suggest that an alteration of TGF β expression may cause an imbalance in growth regulation of stromal and epithelial cells in the prostate. For example, TGF β may have a role in prostate cancer (23, 24). After ablation of androgen by castration, the expression of TGF β 1 in the prostate increases and can be suppressed by *in vivo* treatment with androgen (9, 25). This observation suggests

Received September 24, 1997.

Address all correspondence and requests for reprints to: Michael K. Skinner, Ph.D., Center for Reproductive Biology, Department of Genetics and Cell Biology, Washington State University, Pullman, Washington 99164-4231. E-mail: skinner@mail.wsu.edu.

* This work was supported by NIH Grants DK-45889 and CA-59831.

[†] Current address: Department of Urology, Sapporo Medical University, Sapporo, Japan.

that the expression of TGF β may be regulated by androgen in normal prostate. TGF β has been identified in stromal cells in rat ventral prostate and in an epithelial cell line derived from rat dorsal prostate (26, 27). Cultured human prostatic stromal and epithelial cells have been shown to express TGF β 1, -2, and -3 by RT-PCR (28). The developmental and hormonal regulation of TGF β 1, -2, and -3 has not been thoroughly investigated.

The current study investigates the development and hormonal regulation of TGF β 1, -2, and -3 expression. Isolated epithelial cells and stromal cells from rat ventral prostate were used in the *in vitro* experiments to investigate the actions of testosterone and growth factors.

Materials and Methods

Animals

Male Sprague-Dawley rats were purchased from Bantin-Kingman (Kent, WA). Animals of a variety of ages, including 1-, 20-, 60-, and 100-day-old rats, were used for the study of prostate development. Some of the 60-day-old rats were castrated under avertin anesthesia, which consists of 25 g tribromoethanol in 15.5 ml tertiary amyl alcohol. The prostate glands were removed 3 days after castration. Culture of both prostatic epithelial and stromal cells used 20-day-old rat prostates. Organ culture of ventral prostates used 0-day-old rat prostates. All animal procedures were approved by the university animal care committee.

Culture of ventral prostate cells

The isolated cell cultures used 20-day-old Sprague-Dawley rats; these animals were killed, and ventral prostates were removed. Tissue was incubated with Hanks' Balanced Salt Solution (Life Technologies, Gaithersburg, MD) containing 675 U collagenase activity/ml type II collagenase (Sigma Chemical Co., St. Louis, MO) and 0.04% deoxyribonuclease I (Sigma) at 37 C for 4 h. After incubation, tissue was separated by centrifugation. The mixture was spun at $30 \times g$ for 4 min to pellet the epithelial cells. The remaining supernatant was centrifuged at $190 \times g$ for 6 min to pellet the stromal cells. Both pellets were resuspended and spun at $30 \times g$ for 4 min. The supernatant from stromal cells was removed and repelleted at $190 \times g$ for 6 min. These were then subsequently placed in 10% bovine calf serum F-12 medium in six-well culture plates (Nunclon, Roskilde, Denmark) at 3×10^5 cells/well. After 24 h, the cells were washed in serum-free F-12 medium and incubated for 24 h. On day 3 of culture, the cells were maintained in serum-free conditions and incubated with or without the following treatments: from 10^{-6} - 10^{-9} M testosterone (Sigma), 100 ng/ml EGF (Life Technologies), 25 ng/ml KGF (Life Technologies), 10 ng/ml human recombinant TGF β 1 (Life Technologies), 10% bovine calf serum (HyClone, Logan, UT), and a combination of TGF β 1 and testosterone (10^{-7} M), EGF, or 10% bovine calf serum. The treatments were administered for a period of 72 h. On the sixth day of culture, the medium was removed and stored for measurement of acid phosphatase at -20 C, and cells were harvested for RNA extraction.


Cell purity assay and immunocytochemistry

The purity of ventral prostate stromal and epithelial cells in culture was analyzed by immunohistochemical methods. Isolated stromal or epithelial cells were plated in four-well culture plates at 3×10^5 cells/well on Thermanox coverslips (Nunc, Inc., Naperville, IL). Two days postplating, cells were fixed in 100% methanol for 5 min, then washed in decreasing ethanol conditions and equilibrated in Tris-buffered saline (TBS; pH 7.4). Before antibody staining, the cells were treated with H₂O₂ to quench endogenous peroxidases and then incubated in TBS containing 1% BSA and 0.5% normal serum for 1 h at 20 C. After rinsing three times in TBS, cells were incubated for 2 h at 37 C with either rabbit polyclonal antikeratin (Dako Corp., Carpinteria, CA) or a monoclonal antivimentin (Sigma) antibody at dilutions of 1:250 and 1:300, respectively. Negative controls had no primary antiserum added, and positive controls used epithelial (MCF-10A, human breast) and stromal (SS-140,

human fibroblast) cell lines. After primary antibody incubations, the cells were rinsed three times in TBS and incubated with either goat antirabbit or antimouse IgG horseradish peroxidase-conjugated secondary antibody (Sigma). Visualization was achieved using 50 mM Tris (pH 7.6) containing 0.6% diaminobenzidine and 0.03% H₂O₂ for 10 min at 20 C. The cells were then counterstained in hematoxylin and mounted on slides using an aqueous mounting solution. Stained cells were counted in four separate areas of the slide using cells from five different experiments.

Ventral prostate sections were obtained from 20-day-old Sprague-Dawley rats. Tissue specimens were immediately fixed in Bouin's solution for 3–6 h. Tissue was cut into 5- μ m thick sections, deparaffinized, rehydrated, and treated with an aqueous solution of 3.0% H₂O₂ to quench endogenous peroxidase. After several washes in TBS buffer, sections were incubated in TBS containing 1% BSA for 2 h at 37 C to reduce nonspecific staining. After rinsing three times in TBS, a sheep antirat pan TGF β antibody (East Acres Biological, South Bridge, MA) was added at a 1:500 dilution and incubated overnight at 37 C followed by 2 h at 4 C. For controls, a nonimmune sheep IgG was used at a similar dilution. After three rinses in TBS, the primary antibody was detected with antish sheep biotinylated secondary antibody, and the biotin was detected with an avidin-biotin-peroxidase kit (ABC-Elite, Vector Laboratories, Burlingame, CA). Diaminobenzidine tetrachloride was used as a chromagen, and serial sections were lightly counterstained with hematoxylin.

(A)



(B)




FIG. 1. Relationship between cycle numbers and optimal density as PCR products of TGF β 1, - β 2, and - β 3 and cyclophilin. Values are expressed as the mean \pm SEM ($n = 3$). Linearity between cycle numbers and PCR products are shown in each growth factor as follows: TGF β 1; 25–35; TGF β 2; 27–40; TGF β 3; 30–40; and cyclophilin; 15–30.

RNA preparation

Total RNA was obtained using Tri Reagent (Sigma). Briefly, tissue or cells were lysed in Tri Reagent (1 ml/50–100 mg tissue or 1 ml/10 cm² of culture plate). After adding 0.2 ml chloroform/ml Tri Reagent, the mixture was centrifuged at 12,000 × g for 15 min at 4 C, the colorless upper aqueous phase was transferred to a fresh tube, and 0.5 ml isopropanol/ml Tri Reagent was added to pellet the RNA. The mixture was centrifuged at 12,000 × g for 10 min at 4 C. The RNA pellet was washed with 75% ethanol and resuspended in diethylpyrocabonate (DEPC)-treated H₂O. RNA was stored at -80 C until analysis.

RT

Complementary DNA (cDNA) was synthesized in a total 20-μl volume containing 1 μg total RNA, 0.05 μM of specific 3'-primers (TGFβ1, 5'-GGG GTG GCC ATG AGG AGC AGG-3'; TGFβ2, 5'-GCG CTG GGT GGG AGA TGT TAA-3'; TGFβ3, 5'-CCT TTG AAT TTG ATC TCC A-3'; cyclophilin, 5'-ATT TGC CAT GGA CAA GAT GCC-3'), 4 μl 5 × first strand PCR buffer (Life Technologies), 10 mM dithiothreitol (Life Technologies), 0.125 mM deoxy-NTPs, 100 U Moloney murine leukemia virus transcriptase (Life Technologies), 20 U ribonuclease inhibitor (Promega, Madison, WI), and DEPC-H₂O. Initially, RNA was denatured and annealed in the presence of each primer and DEPC-H₂O at 65 C for 15 min. The tube was placed on ice for 5 min. The other reagents were added to the tube and incubated at 42 C for 2 h. To decrease the high background signal, a higher RT reaction temperature (42 C) was used (29). The mixture was incubated at 95 C for 5 min to inactivate Moloney murine leukemia virus transcriptase. The mixture was diluted by UV-treated H₂O containing Bluescript plasmid DNA (Stratagene, La Jolla, CA) as carrier DNA. The final concentrations of cDNA and Bluescript

plasmid were 1 ng/μl and 10 ng/μl, respectively. This concentration of Bluescript plasmid was included in all samples and standards.

Quantitative PCR assay

As a standard for the assay, PCR products of TGFβ1, -2, and -3 and cyclophilin amplified by each specific primer were subcloned into Blue-




FIG. 3. Expression of mRNA of TGFβ1, -β2, and -β3 in both epithelial cells and stromal cells. Fresh cells that are separated into epithelium and stroma from 20-day-old rat ventral prostate and cells after 6-day culture are analyzed. Values are normalized with cyclophilin and are expressed as the mean ± SEM (n = 4).




FIG. 2. Diluted curve of both plasmid DNA (standard) and total RNA in TGFβ1, -β2, and -β3 and cyclophilin. Values are expressed as the mean ± SEM (n = 2). Parallel relationships in PCR products between plasmid DNA and total RNA are shown.

script plasmid (Stratagene). Each subclone was sequenced in both directions and confirmed to be rat TGFβ1, -2, and -3 and cyclophilin. The size and base pair alignment of the PCR product generated were as follows: 200 bp size from 1003–1203 bp alignment on the coding sequence (accession no. 52498; TGFβ1), 194 bp size from 355–549 bp alignment on the coding sequence (TGFβ2), 288 bp size from 865–1153 bp alignment on the coding sequence (accession no. 403491; TGFβ3), and 105 bp size from 244–348 bp alignment on the coding sequence (accession no. M19533; cyclophilin). Plasmid DNA containing TGFβ subclones was used to generate standard curves ranging from 0.1 fg/μl to 1.0 pg/μl, and for cyclophilin from 10 fg/μl to 100 pg/μl. PCR was performed on a Perkin-Elmer GeneAmp PCR System 9600 (Perkin-Elmer, Branchburg, NJ) and was carried out in a total 25-μl reaction volume containing 5 μl plasmid DNA or RT reaction, 0.4 μM 3'-primer as shown above, 0.4 μM 5'-primer (TGFβ1, 5'-TCG ATT TTG ACG TCA CTG GAG TTG T-3'; TGFβ2, 5'-CCG CCC ACT TTC TAC AGA CCC-3'; TGFβ3, 5'-TGC CCA ACC CGA GCT CTA AGC G-3'; cyclophilin, 5'-ACA CGC

CAT AAT GGC ACT GG-3'), 2.5 μl 10 × GeneAmp PCR buffer (containing 1.5 mM MgCl₂; Perkin-Elmer), 25 μM deoxy-NTPs, 0.5 U Taq DNA polymerase (Perkin-Elmer), and 1 μCi [α -³²P]deoxy-CTP (Amersham Life Science, Arlington Heights, IL).

The TGFβ1 reaction cycle sequence comprised 5 min at 95 C, followed by 30 cycles of 1 min at 95 C, 1 min at 60 C, and 2 min at 72 C. The cyclophilin reaction cycle sequence comprised 5 min at 95 C, followed by 25 cycles of 1 min at 95 C, 1 min at 60 C, and 2 min at 72 C. The TGFβ2 reaction cycle sequence comprised 5 min at 95 C, followed by 33 cycles of 1 min at 95 C, 2 min at 60 C, and 3 min at 72 C. The TGFβ3 reaction cycle sequence comprised 5 min at 95 C, followed by 35 cycles of 1 min at 95 C, 2 min at 55 C, and 3 min at 72 C. All reactions had a final extension for 10 min at 72 C.

After PCR, the products were electrophoretically separated on a 6% acrylamide gel. The gel was then dried and analyzed on a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) quantitatively. Each gene was assayed in separate PCR reactions from the same RT samples.

FIG. 4. Changes in the relative expression of TGFβ1, -β2, and -β3 during development of rat ventral prostate. Values are normalized with cyclophilin and compared with those of 20-day-old rats as relative expression and presented as the mean ± SEM (n = 3–5). Statistical difference is indicated by different letter superscripts (P < 0.05).





FIG. 5. Relative expression of TGFβ1 (A), TGFβ2 (B), and TGFβ3 (C) in cultured rat ventral prostate with or without treatment. Values are normalized with cyclophilin and are presented as the relative expression compared with control cultures. Values were expressed as the mean ± SEM (n = 4–12). Statistical difference is indicated by different letter superscripts (P < 0.05).

Equivalent steady state messenger RNA (mRNA) levels for each gene were determined by comparing each sample to the appropriate standard curve. TGF β 1, -2, and -3 were normalized for cyclophilin. For each assay, all samples were simultaneously measured in duplicate with intraassay variabilities of 7.5% (TGF β 1), 9.4% (TGF β 2), 9.9% (TGF β 3), and 9.2% (cyclophilin).

Cell growth assay

Cell growth was analyzed by examining [3 H]thymidine incorporation into newly synthesized DNA. Stromal and epithelial cells were placed at subconfluent densities (<1 million cells/cm 2) in 0.5 ml DMEM containing 0.1% calf serum. The low serum level does not stimulate growth and is required for progression factors (*i.e.* insulin-like growth factor) for the S phase of the cell cycle to detect the growth factor response. After 48–72 h of culture, the cells were treated with various agents for 24 h. After the 24-h treatment, 0.5 ml DMEM containing 2 μ Ci [3 H]thymidine was added to each well, and the cells were incubated for 4 h at 37 C before sonication. The quantity of [3 H]thymidine incorporated into DNA was determined as previously described (30). Data were normalized to total DNA per well using an ethidium bromide procedure, described previously (31). Under these subconfluent culture conditions, approximately 0.5–1.5 μ g DNA were detected per well. [3 H]Thymidine incorporation was generally greater than 2×10^3 cpm/ μ g DNA.

Organ culture of rat ventral prostate

Ventral prostates were removed from 0-day-old rats and cultured in a drop of medium on a Millicell CM filter (Millipore, Bedford, MA) floating on the surface of 0.5–1.0 ml CMRL 1066 medium (Life Technologies, Gaithersburg, MD) supplemented with penicillin-streptomycin, insulin (10 μ g/ml), and transferrin (10 μ g/ml) with or without treatments. The cultures were performed in a four-well Nunclon surface dish (32). These plates were placed in the incubator at 37 C in an atmosphere of 5% CO $_2$ and 95% air. The tissues were cultured for 6 days. Treatments were testosterone (Sigma; 10^{-7} M), EGF (Life Technologies; 100 ng/ml), TGF β 1 (Life Technologies; 10 ng/ml), and a combination of testosterone and EGF or a combination of testosterone and TGF β 1. Images of the prostates were captured with an image analysis system (Pixera, Pixera Corp., Los Gatos, CA). At the end of the culture, the organs were fixed for histology. The analysis and quantitation of ductal branching morphogenesis were previously described (32).

Statistical analysis

All data were analyzed by a JMP 3.1 statistical analysis program (SAS Institute, Cary, NC). All values are expressed as the mean \pm SEM. Statistical analysis was performed using one-way ANOVA. Significant differences were determined using the Dunnett's test for comparison to controls and using the Tukey-Kramer honestly significant difference test for multiple comparisons. Statistical difference was confirmed at $P < 0.05$.

Results

Characterization of the quantitative RT-PCR (QRT-PCR) for TGF β 1, -2, and -3 and cyclophilin

Preliminary studies were performed to establish a reproducible and accurate QRT-PCR procedure. The linearity of generating a PCR product relative to cycle number was determined (33). The PCR product for TGF β 1 increased at 25 cycles and reached a plateau at 36 cycles. Thirty cycles was selected to be an appropriate cycle number for QRT-PCR (Fig. 1A). The TGF β 2 PCR product continued to be amplified at 42 cycles. For TGF β 2, 33 cycles was midpoint on the linear amplification of the PCR product and was selected for QRT-PCR (Fig. 1A). TGF β 3 product started to increase after 30 cycles and reached a plateau level at 40. Thirty-five cycles was determined appropriate to use for TGF β 3 (Fig. 1B). For




FIG. 6. The [3 H]thymidine incorporation growth assay on cultured rat ventral prostate cells. Values are expressed as the mean \pm SEM ($n = 3$; control = 1). Statistical difference is indicated by different letter superscripts ($P < 0.05$).

cyclophilin, 25 cycles was determined to be the appropriate cycle number (Fig. 1B).

Another aspect of the QRT-PCR procedure involves a comparison of standard DNA with unknown samples for parallel displacement. Plasmid DNA with subcloned PCR product and cDNA produced from unknown RNA samples were run in parallel. PCR products of diluted plasmid DNA and diluted unknown cDNA were compared. These two curves were parallel with each growth factor, indicating that the QRT-PCR assay could be used to quantitate mRNA levels (Fig. 2, A–D). The small error shown in each of the data points demonstrates minimal variability in the assay (Figs. 1 and 2).

Comparison of growth factor expression in fresh and cultured stromal and epithelial cells

Analysis of TGF β 1, -2, and -3 mRNA expression in both stromal and epithelial cells of rat ventral prostate was determined. The differences in the expression pattern of these products between freshly isolated ventral prostate cells and cultured cells was investigated. In freshly isolated cells from 20-day-old rat prostate, TGF β expression normalized by cyclophilin ranged from 0.3 – 6×10^{-3} fg TGF β /fg cyclophilin (Fig. 3). Expression of TGF β 1 and -2 was higher in stromal




FIG. 7. Ventral prostate after 6 days of treatment with testosterone (10^{-7} M), EGF (100 ng/ml), TGF β 1 (10 ng/ml), or their combination in organ culture. These ventral prostates were removed from 0-day-old Sprague-Dawley rats. Data are representative of three different experiments performed in replicate.

cells than in epithelial cells. TGF β 3 expression in epithelial cells was the same as that in stromal cells. In cultured samples derived from 20-day-old rat ventral prostate, TGF β 1, -2, and -3 showed higher expression than fresh samples and ranged from $7\text{--}700 \times 10^{-3}$ fg TGF β /fg cyclophilin. Contrary to that in fresh samples, expression in epithelial cells in cultured samples was higher than that in stromal cells. In both epithelial and stromal cells, TGF β 1 had the lowest level of expression, and TGF β 3 had the highest level of expression (Fig. 3).

Developmental regulation of TGF β expression in rat prostate

To investigate the changes in TGF β 1, -2, and -3 expression during rat development from the neonatal period (1-day-old

to adulthood (100-day-old), ventral prostates were removed from rats aged 1, 20, 60, and 100 days, and the mRNA expression of TGF β was measured by QRT-PCR. The effects of androgen depletion on TGF β 1, -2, and -3 expression were analyzed by castration of 60-day-old rats. The expression of TGF β isoforms was normalized by cyclophilin expression, and relative expression was compared with that in 20-day-old rats. TGF β 1 expression did not vary during development (Fig. 4). After castration of 60-day-old rats, TGF β 1 significantly increased to 5-fold that in 60-day-old rats. During the neonatal period, TGF β 2 expression was elevated, then decreased in pubertal and early adult periods (60 days of age) and was elevated in adult rats (100 days old). After castration, TGF β 2 was increased 4-fold, but remained lower than that in 100-day-old rats. In contrast to TGF β 2, TGF β 3 ex-

pression was very low in the 1- and 100-day-old prostates and was elevated during the pubertal and early adult periods (60 days of age). After castration, TGF β 3 expression was significantly suppressed from that in 60-day-old rats. Interestingly, TGF β 3 expression was inversely related to TGF β 2 expression (Fig. 4).

Hormonal regulation of TGF β expression in cultured prostate cells

The effects of testosterone and growth factors on TGF β 1, -2, and -3 expression were investigated in stromal and epithelial cells derived from ventral prostate of 20-day-old rats. EGF and KGF were used as stimulatory growth factors, and human recombinant TGF β 1 was used as an inhibitory growth factor. TGF β 1 was combined with testosterone or EGF to study potential suppressive effects. All values were normalized with cyclophilin and expressed as relative expression compared with that in control cultures.

Analysis of cell purity indicated that isolated epithelial cells showed $93.2 \pm 1.2\%$ (mean \pm SEM; $n = 5$) keratin-positive cells and less than 3% vimentin-positive cells. Isolated stromal cells showed $86.0 \pm 3.5\%$ (mean \pm SEM; $n = 5$) vimentin-positive and less than 5% keratin-positive cells. These results demonstrate that cell purity in both isolated stromal and epithelial cells were appropriate for data interpretation.

EGF significantly stimulated (6-fold) TGF β 1 expression in stromal cells (Fig. 5A) and significantly stimulated the expression of TGF β 1 in epithelial cells at a reduced level (2.5-fold) compared to that in stromal cells. This effect was not significantly different compared with that of other treatments, but was different from the control. TGF β 1 had no effect on the expression of TGF β 1 in either stromal or epithelial cells. The effects of EGF on TGF β 1 expression were not influenced by exogenous administration of TGF β 1 in either cell type. Neither testosterone nor KGF had any effect on TGF β 1 expression in either cell type (Fig. 5A).

In stromal cells, the expression of TGF β 2 was elevated to approximately 1.5-fold by each treatment; however, these effects were not statistically significant (Fig. 5B). In epithelial cells, only KGF significantly stimulated (2.8-fold) TGF β 2 expression. TGF β 1 alone did stimulate TGF β 2 expression, but this stimulation was not statistically different from that in control cultures (Fig. 5B). Results indicate that prostate stromal cells were not influenced by any treatment, and epithelial cells were only influenced by KGF with regard to TGF β 2 expression.

No treatment affected TGF β 3 expression in either stromal or epithelial cells (Fig. 5C). Although small effects were observed with testosterone and TGF β 1, these were not statistically different from those in control cultures.

Combined observations indicate that EGF regulates TGF β 1 expression by stromal and epithelial cells, KGF regulates TGF β 2 expression by epithelial cells, and none of the treatments used in the current study influences TGF β 3 expression. Testosterone had no effect on TGF β 1, TGF β 2, or TGF β 3 in either cell type.

Regulation of prostate cell growth

Stromal and epithelial cells from rat ventral prostates were cultured to examine the effects of testosterone, EGF, KGF, and TGF β 1 on cell growth. A tritiated thymidine incorporation assay was performed using 10% bovine calf serum as a positive control. Calf serum significantly stimulated (\sim 4-fold) DNA synthesis in both stromal and epithelial cells (Fig. 6). Testosterone and EGF stimulated (2.5- to 3-fold) DNA synthesis in stromal and epithelial cells. KGF had a stimulatory effect on epithelial cells. TGF β had no direct effect on DNA synthesis alone (Fig. 6). However, TGF β significantly inhibited the growth effects of testosterone and EGF on stromal cells as well as the growth effects of testosterone on epithelial cells. These results indicate that testosterone and EGF can stimulate the growth of both stromal cells and epithelial cells, whereas TGF β can inhibit these actions and suppress growth. Although the growth response for testosterone was observed in less than 24 h, potential indirect effects of testosterone mediated by other peptide growth factors remain to be elucidated.

Regulation of ductal branching morphogenesis

To address the potential physiological function of TGF β , an organ culture of 0-day-old rat prostate was used. Prostate organ cultures can be used to analyze the effects of growth factors on the whole organ, in which normal cell to cell interactions are intact (32). Testosterone (10^{-7} M) treatment of prostate organ cultures promoted significant branching morphogenesis compared with that in control cultures (Fig. 7). TGF β 1 alone caused a slight reduction in the number of branching ducts, but the number was similar to that in control cultures. However, TGF β 1 completely inhibited the stimulatory effect of testosterone on prostatic ductal branching morphogenesis (Figs. 7 and 8). EGF increased prostatic size; however, ductal branching was significantly reduced (Figs. 7 and 8), and ducts were swollen, with an increase in surrounding stromal layers (Fig. 7). The histology of these organ cultures is shown in Fig. 9 and demonstrates that EGF does increase the stromal/epithelial cell ratio as well as shows the




FIG. 8. Number of branching ducts in 0-day-old rat ventral prostate organ cultures, presented as the number of tips per mm². Data were obtained from images similar to those represented in Fig. 7. Data are expressed as the mean \pm SEM ($n = 3$). Different superscript letters indicate a statistical difference ($P < 0.05$).




FIG. 9. Histology of 0-day-old rat ventral prostate organ cultures after 6 days of culture. Data are presented at two magnifications, as indicated with the treatments presented. Data are representative of three different experiments.

epithelial cells are less organized into ductal structures. Testosterone promotes a polarized epithelial cell morphology, whereas EGF promotes a more random proliferation of the epithelium (Fig. 9). A combination of testosterone and EGF caused enlargement of the prostate; however, this enlargement was not due to ductal formation and appears to be due to stromal enlargement (Figs. 7 and 8). The degree of ductal branching morphogenesis with testosterone and EGF was increased over that with EGF alone (Fig. 8). The ratio of stroma/epithelium was higher in the prostates treated with EGF than in control cultures. Combined results indicate that TGF β can inhibit the stimulatory effects of testosterone on prostate morphogenesis. The ability of EGF to stimulate TGF β may have a role in the inhibitory effects of EGF on prostate ductal branching morphogenesis.

TGF β cellular localization

To address the *in vivo* localization of TGF β , a pan-TGF β antibody that recognizes all three forms of TGF β was used in immunocytochemistry of 20-day-old rat prostate sections. TGF β protein was predominantly found in the stromal cell

population, with only sparse staining in the epithelium (Fig. 10). TGF β staining was most intense in the stromal cells adjacent to the epithelial cells. Although the mRNA for TGF β was found in both cell types, the protein is primarily localized in stromal cells. Whether this is due to localization in the extracellular environment of the stromal cells or is a reflection of production levels remains to be elucidated. Controls with nonimmune IgG had no staining detected (Fig. 10).

Discussion

The current study was designed to investigate the developmental and hormonal regulation of TGF β expression in the prostate. Previously, the three isoforms of TGF β were shown to be present in normal prostate, benign prostatic hyperplasia (BPH), and prostate cancer by Northern blot and ribonuclease protection assays (26, 27, 34). Recently, TGF β 1, -2, and -3 mRNA were detected in stromal and epithelial cells of normal human prostate and BPH by RT-PCR (28). For the current study, a sensitive QRT-PCR procedure was developed to accurately investigate the regulation of TGF β expression. This QRT-PCR procedure was specific for the dif-




FIG. 10. Immunocytochemical localization of TGF β in 20-day-old rat prostate sections. Sections were incubated in the presence of nonimmune antibody (B and D) or in the presence of a pan-TGF β antibody (A and C). Data are representative of three different experiments.

ferent TGF β isoforms and used small amounts of tissue or cells. All data obtained for TGF β were normalized for a constitutively expressed gene, cyclophilin. Cyclophilin expression did not change among the samples (data not shown) and was corrected for variations in RNA amount and integrity. The QRT-PCR procedure developed was useful to investigate TGF β expression.

All three isoforms of TGF β , TGF β 1, -2, and -3, were expressed in both stromal cells and epithelial cells from freshly isolated cells and cultured cells. Freshly isolated prostatic stromal cells have a higher level of TGF β expression than epithelial cells. TGF β 3 has the highest level of expression, whereas TGF β 1 has the lowest. The high levels of TGF β mRNA in freshly isolated stromal cells correlated to the immunocytochemical data, with TGF β staining predominantly in the stromal cells. However, epithelial cells did express all isoforms of TGF β . During cell culture, the levels of TGF β 1, -2, and -3 increased in both cell types. Interestingly, the epithelial cells developed a higher level of expression than stromal cells in culture. This increase in expression during culture may be due to the lack of regulatory agents that suppress expression in normal *in vivo* tissue. Previously, the type I and type II TGF β receptors (15) have been shown to be expressed in the prostate (35). These observations suggest that both prostate stromal and epithelial cells have the capacity to express TGF β 1, -2, and -3, which may act as both paracrine and autocrine factors to influence prostate function.

The developmental regulation of TGF β 1, -2, and -3 expression was investigated with neonatal day 0 rats, pubertal day 20 rats, early adult day 60 rats, and adult day 100 rats. TGF β 1 expression (*i.e.* mRNA levels) remained constant during prostate development. TGF β 2 expression was high during the neonatal and adult (100 day) periods and low during the pubertal and early adult (60 day) periods. In contrast, TGF β 3 expression was low during the neonatal and adult (100 day) periods and high during the pubertal and early adult (60 day) periods. TGF β 2 and TGF β 3 expression appeared to be inversely related during prostate development. Recently, the ratio of stromal to epithelial cells was measured during prostate development and was constant throughout (36). Therefore, the changes in TGF β 1, -2, and -3 do not appear to be due to alterations in the cell populations. Although the three isoforms of TGF β are highly homologous and have similar biological activities, the developmental expression during prostate development appears distinct. The inverse relation of TGF β 2 and TGF β 3 may reflect changes in the regulation of prostate function and may be required to coordinate local cell-cell interactions (37).

Androgens are postulated to be an essential factor to regulate TGF β expression in the prostate (9, 25). Both TGF β 1 and TGF β 2 expression increased after castration. This supports previous observations with TGF β 1 (9, 10). Interestingly, TGF β 3 expression decreased after castration. Previously, TGF β 2 mRNA levels have been shown to be negatively correlated with androgen levels in both normal and malignant prostate (34). The changes in TGF β expression during development cannot be directly correlated with serum androgen levels. The relationship of serum androgen levels and TGF β expression remains to be elucidated. As discussed

below, androgens have no effect on TGF β expression using cultured prostate cells. Another factor to explain the changes after castration is the alteration in the stromal/epithelial cell populations (36). These observations suggest that the relationship of TGF β expression and androgen levels remains to be elucidated and probably involves a combination of direct and indirect actions of androgens.

Several interesting observations came from the analysis of TGF β expression in cultured prostatic stromal and epithelial cells. Both isolated cell populations were approximately 90–95% pure by an immunocytochemical analysis of the cell populations. Androgens did not influence TGF β 1, -2, or -3 in either stromal cell or epithelial cell cultures. The concentrations of androgen used ranged from 10^{-8} – 10^{-6} M, with no effect at any concentration (data not shown). This observation suggests that androgen may not have a dramatic direct action on TGF β expression. TGF β 3 expression was not influenced by any of the treatments used in the current study. TGF β 2 was also not affected in stromal cells by any treatment. KGF stimulated TGF β 2 in epithelial cells. KGF has been shown to mediate stromal-epithelial cell interactions in the prostate and to influence prostate morphogenesis (3, 32, 36). The ability of KGF to influence TGF β 2 expression in prostate epithelium will probably have a role in the actions of KGF on the prostate.

TGF β had no effect on TGF β 1, -2, or -3 expression in either stromal cells or epithelial cells. Previously, TGF β 1 was found to enhance bFGF expression in cultured human prostatic stromal cells (13, 14). In rat kidney fibroblasts, TGF β has been shown to stimulate TGF β expression (38). In the current study, TGF β did not have a major regulatory role in the control of TGF β expression.

Perhaps one of the more interesting observations made was the effect of EGF on TGF β 1 expression. EGF stimulated the expression of TGF β 1 by both prostatic stromal and epithelial cells. EGF has been shown to be a potent growth stimulator of prostatic epithelium (39, 40). The observations made in the current study suggest that EGF may also have an important regulatory role. The actions of EGF on prostate function and development discussed below will probably be mediated in part by these effects on TGF β 1 expression.

The effects of TGF β on cell growth were examined to investigate the functional significance of TGF β in the prostate. Both EGF and testosterone dramatically stimulated prostate stromal and epithelial cell growth. The potential indirect actions of testosterone via peptide growth factors need to be considered. TGF β inhibited the actions of testosterone and EGF on both cell types. This correlates with the previously identified function of TGF β as a growth inhibitory substance. Previously, TGF β has been shown to inhibit the growth of human prostate epithelial cells (21). An important function for TGF β will probably be as a growth inhibitor in the prostate.

Another functional parameter of the prostate examined was ductal branching morphogenesis in prostate organ cultures. This organ culture system has been developed to investigate morphogenesis of the prostate and actions of agents such as androgens and KGF (36, 32). In the current study, androgen was found to promote ductal branching morphogenesis, and TGF β was found to suppress the actions of

androgens. This suggests that TGF β may have a role in regulating prostate morphogenesis. Interestingly, EGF also dramatically suppressed ductal branching morphogenesis. This was in part due to a proliferation of stromal cells and a disorganization of the epithelium. The ability of TGF β to suppress ductal branching morphogenesis and inhibit EGF-stimulated growth suggests that TGF β may have a role in this process. In support of this proposal is the ability of EGF to stimulate TGF β 1 expression. These observations suggest that TGF β will have a role in prostate growth and morphogenesis. The actions of regulatory agents (e.g. EGF) on the prostate may be mediated indirectly through the production and action of TGF β .

The combined observations suggest that a network of locally produced growth factors, such as KGF, EGF, and TGF β , will coordinate prostate development and morphogenesis. This is supported by observations in the current study regarding the developmental and hormonal regulation of TGF β 1, -2, and -3 expression in prostate stromal and epithelial cells. Regulatory agents such as androgen probably involved both direct and indirect actions mediated through this network of growth factors to control prostate function. The abnormal phenotypes in prostate cancer and BPH will probably in part be due to the inability of this network of regulatory agents and growth factors to maintain normal prostate function. It is speculated that TGF β will have a role in this process.

Acknowledgments

We thank Linda Miyashiro and Eugene Herrington for technical assistance, and Susan Cobb for assistance with the preparation of the manuscript. We also thank Dr. Jeff Parrott for advice and assistance. We acknowledge the helpful interactions and discussions with Gerald Cunha and his laboratory at University of California-San Francisco.

References

- Davies P, Eaton CL 1991 Regulation of prostate growth. *J Endocrinol* 131:5-17
- Tennswood M 1986 Role of epithelial-stromal interactions in the control of gene expression in the prostate: an hypothesis. *Prostate* 9:375-385
- Cunha GR 1996 Growth factors as mediators of androgen action during male urogenital development. *Prostate* 6:22-25
- Chung LWK, Gleave ME, Hsieh J, Hong S, Zhou HE 1991 Reciprocal mesenchyme-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. In: Isaacs JT (ed) *Prostate Cancer Cell and Molecular Mechanisms in Diagnosis and Treatment*. Cold Spring Harbor Laboratory, New York, pp 91-122
- Cunha GR, Alarid ET, Turner A, Donjacour AA, Boutin EL, Foster BA 1992 Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. *J Androl* 13:465-475
- Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H 1996 Regulation of prostatic growth and function by peptide growth factors. *Prostate* 28:392-405
- Steiner M 1993 Role of peptide growth factors in the prostate: a review. *Urology* 42:99-110
- Byrne RL, Leung H, Neal DE 1996 Peptide growth factors in the prostate as mediators of stromal epithelial interaction. *Br J Urol* 77:627-633
- Kyprianou N, Isaacs JT 1989 Expression of transforming growth factor- β in the rat ventral prostate during castration-induced programmed cell death. *Mol Endocrinol* 3:1515-1522
- Nishi N, Oya H, Matsumoto K, Nakamura T, Miyataka H, Wada F 1996 Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates. *Prostate* 28:139-152
- Hiramatsu M, Kashimata M, Minami N, Sato A, Murayama M 1988 Androgen regulation of epidermal growth factor in the mouse ventral prostate. *Biochem Int* 17:311-317
- Katz AE, Benson MC, Wise GJ, Olsson CA, Bandyk MG, Sawczuk IS, Tomashefsky P, Buttyan R 1989 Gene activity during the early phase of androgen-stimulated rat prostate regrowth. *Cancer Res* 49:5889-5894
- Story MT, Hopp KA, Meier DA, Begun FP, Lawson RK 1993 Influence of transforming growth factor β 1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts. *Prostate* 22:183-197
- Story MT, Hopp KA, Meier DA 1996 Regulation of basic fibroblast growth factor expression by transforming growth factor- β in cultured human prostate stromal cells. *Prostate* 28:219-226
- Massague J 1990 The transforming growth factor- β family. *Annu Res Cell Biol* 6:597-641
- Chambaz EM, Souchevnik S, Pellerin S, Defaye G, Cochet C, Feige J 1996 Transforming growth factor β s: a multifunctional cytokine family. *Horm Res* 45:222-226
- Saltis J 1996 TGF- β : receptors and cell cycle arrest. *Mol Cell Endocrinol* 116:227-232
- Polyak K 1996 Negative regulation of cell growth by TGF- β . *Biochim Biophys Acta* 1242:185-199
- Ilio KY, Sensibar JA, Lee C 1995 Effect of TGF- β 1 and TGF- α EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. *J Androl* 16:482-490
- McKeehan WL, Adams PS, Rosser MP 1984 Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum free, primary cell culture. *Cancer Res* 44:1998-2010
- Sutfowski DM, Fong CJ, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, Lee C 1992 Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture. *Prostate* 21:133-143
- Martikainen P, Kyprianou N, Issacs JT 1990 Effect of transforming growth factor- β 1 on proliferation and death of rat prostatic cells. *Endocrinology* 127:2963-2968
- Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC 1993 Association of transforming growth factor- β 1 with prostate cancer: an immunohistochemical study. *Hum Pathol* 24:4-9
- Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC 1995 Transforming growth factor- β 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. *Lab Invest* 73:628-635
- Bacher M, Rausch U, Goebel HW, Polzar B, Mannherz HG, Aumuller G 1993 Stromal and epithelial cells from rat ventral prostate during androgen deprivation and estrogen treatment-regulation of transcription. *Exp Clin Endocrinol* 101:78-86
- Danielpour D 1996 Induction of transforming growth factor- β autocrine activity by all-*trans*-retinoic acid and $1\alpha,25$ -dihydroxyvitamin D $_3$ in NRP-152 rat prostatic epithelial cells. *J Cell Physiol* 166:231-239
- Timme TL, Truong LD, Slawin KM, Kadmon D, Park SH, Thompson TC 1995 Mesenchymal-epithelial interactions and transforming growth factor- β 1 expression during normal and abnormal prostatic growth. *Micro Res Technique* 30:333-341
- Story MT, Hopp KA, Molter M 1996 Expression of transforming growth factor beta 1 (TGF- β 1), - β 2, and - β 3 by cultured human prostate cells. *J Cell Physiol* 169:97-107
- Freeman WM, Vrana SL, Vrana KE 1996 Use of elevated reverse transcriptional reaction temperatures in RT-PCR. *Biotechniques* 20:782-784
- Skinner MK, Fritz IB 1986 Identification of a non-mitogenic paracrine factor involved in mesenchymal-epithelial cell interactions between testicular peritubular cells and Sertoli cells. *Mol Cell Endocrinol* 44:85-97
- Roberts AJ, Skinner MK 1990 Hormone regulation of thecal cell function during antral follicle development in bovine ovaries. *Endocrinology* 127:2907-2917
- Sugimura Y, Foster BA, Hom YK, Lipschutz JH, Rubin JS, Finch PW, Aaronson SA, Hayashi N, Kawamura J, Cunha GR 1996 Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. *Int J Dev Biol* 40:941-951
- Ma YJ, Costa ME, Ojeda SR 1994 Developmental expression of the genes encoding transforming growth factor alpha and its receptor in the hypothalamus of female rhesus macaques. *Neuroendocrinology* 60:346-359
- Knabbe C, Klein H, Zugmaier G, Voigt KD 1993 Hormonal regulation of transforming growth factor β -2 expression in human prostate cancer. *J Steroid Biochem* 47:137-142
- Kim IY, Ahn HJ, Zeiner DJ, Park L, Sensibar JA, Lee C 1996 Expression and localization of transforming growth factor- β receptors type I and type II in the rat ventral prostate during regression. *Mol Endocrinol* 10:107-115
- Thomson AA, Foster BA, Cunha GR 1997 Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. *Development* 124:2431-2439
- Cox DA 1995 Transforming growth factor- β 3. *Cell Biol Int* 19:357-371
- Obberghen-Schilling EV, Roche NS, Flanders KC, Sporn MB, Roberts AB 1988 Transforming growth factor β 1 positively regulates its own expression in normal and transformed cells. *J Biol Chem* 16:7741-7746
- Levine AC, Ren M, Huber GK, Kirschenbaum A 1992 The effect of androgen, estrogen and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates. *Endocrinology* 130:2413-2419
- Marengo SR, Chung LWK 1994 An orthotopic model for the study of growth factors in the ventral prostate of the rat: effects of epidermal growth factor and basic fibroblast growth factor. *J Androl* 15:277-286